Boehringer's diabetes drug patent revoked by JPO, appeal pending at Japan's IP High Court
The Japan Patent Office has invalidated a key Boehringer Ingelheim patent covering the dosage use of its DPP-IV inhibitor linagliptin for type 2 diabetes, siding with arguments from generics manufacturers that...To view the full article, register now.
Already a subscriber? Click here to view full article